Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
FINASTERIDE
Actavis Group PTC ehf
G04CB01
FINASTERIDE
5 Milligram
Film Coated Tablet
Product subject to prescription which may not be renewed (A)
Testosterone-5-alpha reductase inhibitors
Authorised
2009-01-09
1 PACKAGE LEAFLET: INFORMATION FOR THE USER PROFAL 5 MG FILM COATED TABLETS Finasteride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Profal is and what it is used for 2. What you need to know before you take Profal 3. How to take Profal 4. Possible side effects 5. How to store Profal 6. Contents of the pack and other information 1. WHAT PROFAL IS AND WHAT IT IS USED FOR Profal contains the active substance finasteride which belongs to a group of medicines called ‘5-alpha reductase inhibitors’. They act by reducing the size of the prostate gland in men. Profal is used in the treatment and control of benign (not cancerous)_ _enlargement of the prostate. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PROFAL DO NOT TAKE PROFAL: - if you are allergic to finasteride or any of the other ingredients of this medicine (listed in section 6). - if you are a woman or a child (see also ‘Pregnancy and breast-feeding’ in this section). WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Profal - if you have reduced liver function. - if you have difficulty emptying your bladder completely or a greatly reduced flow of urine, your doctor should examine you thoroughly_ _before you start taking Profal to exclude other obstructions in the urinary tract. - if you notice any changes in your breast tissue such as lumps, pain, enlargement of the breast tissue or nipple discharge as these may be signs of a serious condition, such as breast cancer. You should promptly report to your doctor if you Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Profal 5 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 5 mg finasteride. Excipient with known effect: Each film-coated tablet contains 90.96 mg lactose monohydrate. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet Blue, round biconvex tablet marked “F5”. The diameter is 7 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Profal is indicated for the treatment and control of benign prostatic hyperplasia (BPH) in patients with an enlarged prostate to: cause regression of the enlarged prostate, improve urinary flow and improve the symptoms associated with BPH reduce the incidence of acute urinary retention and the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. Profal 5 mg tablets should only be administered in patients with an enlarged prostate (prostate volume above ca. 40 ml). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For oral use only. The recommended dosage is one 5 mg tablet daily with or without food. The tablet should be swallowed whole and must not be divided or crushed (see section 6.6). Even if improvement can be seen within a short time, treatment for at least 6 months may be necessary in order to determine objectively whether a satisfactory response to treatment has been achieved. Dosage in hepatic insufficiency There are no data available in patients with hepatic insufficiency (see section 4.4). Dosage in renal insufficiency Dosage adjustments are not necessary in patients with varying degrees of renal insufficiency (with creatinine clearance down to as low as 9 ml/min) as in pharmacokinetic studies renal insufficiency was not found to affect the elimination of finasteride. Finasteride has not been studied in patients on haemodialysis. Dosage in the elderly Dosage adjustments are not necessary although pharmacokinetic studies have shown that the elimination rate of H E A L T H P R O D U C T S Read the complete document